Transparency Market Research, in a report titled “G-Protein Coupled Receptors Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2022,” carefully examines the performance and contribution of the global market. Based on the findings of the report, the global GPCRs market is anticipated to increase in value from US$1.6 bn in 2013 to US$3.5 bn by 2022 at a strong 8.80% CAGR therein.
The global market for GPCRs is fueled by the increased prevalence and incidence of various respiratory, cardiovascular, and reproductive disorders, the growing demand for improved GPCR assays in drug discovery, the alarming rise in the incidence of cancer and disorders of the central nervous system, and the surge in government initiatives. While the development of technologically advanced GPCR assays, assay platforms, and assay systems is likely to provide significant opportunities for growth for players within the GPCRs market, the high cost involved in terms of instruments, equipment, and the maintenance of cell lines is anticipated to hamper the expansion of the GPCRs market.
Download free exclusive Brochure of this report:
By assay type, the market for GPCRs is divided into GTPγS binding, reporter gene, cAMP, calcium level detection, cGMP, and receptor internalization. The cAMP assays category emerged as the dominant segment in 2013, fueled by the growing demand for these assays in high throughput screening and several drug discovery platforms. The wide applicability of cAMP assays and the introduction of advanced versions is likely to continue driving the demand for these assays.
Based on therapeutic area, the GPCRs market has been categorized into central nervous system, immune system, oncology, cardiovascular system, respiratory system, reproductive system, and others. In 2013, oncology emerged as the largest therapeutic area segment of the GPCRs market, propelled primarily by the rising incidence of various cancers around the world.
The GPCRs market has been geographically segmented into North America, Europe, Asia Pacific, and Rest of the World. North America, followed by Europe, is the leading market for GPCRs, driven mainly by the alarming rise in obesity-related disorders and the surge in geriatric population. Excessive intake of nicotine and alcohol, unhealthy eating habits, and a sedentary lifestyle have contributed toward the rise in lifestyle-related disorders. The GPCRs markets in these regions are also fueled by the increase in research and development activities in the development of high-efficacy therapeutic drugs.
Asia Pacific is likely to emerge as a strong contender in the GPCRs market, expanding at the highest CAGR during the forecast period. Improving healthcare infrastructure, the expansion of major pharmaceutical companies and CROs, untapped opportunities in emerging countries, rising geriatric population, and a surge in research and development activities make Asia Pacific a highly lucrative market for GPCRs.
Some of the prominent players in the global GPCRs market are Enzo Life Sciences, Inc., Becton, Dickinson and Company, Abcam plc, Sigma-Aldrich Corporation, Promega Corporation, Cisbio Bioassays, HD Biosciences Co. Ltd., EMD (Merck) Millipore, PerkinElmer, Inc., Thermo Fisher Scientific, Inc., QIAGEN N.V., and DiscoveRx Corporation. These players have been reviewed in the report based on attributes such as company and financial overview, business strategies, recent developments, and product portfolio.